Research Reference
Semax
ACTH-derived nootropic — BDNF upregulation and cognitive research
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Semax is a synthetic heptapeptide analog of ACTH(4-10) — the fragment of adrenocorticotropic hormone responsible for cognitive effects without hormonal activity. Approved in Russia for cognitive disorders and ischemic stroke, it has documented BDNF upregulation and neuroprotective effects.
Semax is not FDA-approved. It has clinical approval in Russia only.
Standard protocol: 1 mg subcutaneous in the morning, 2–3 days per week, 8 weeks on / 8 weeks off. Semax has mild stimulatory effects — community sources describe dosing before cognitive tasks and avoiding late evening dosing.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 10 mg vial. Resulting concentration: 5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 1 mg | 20 units | 0.2 mL | 2–3x/week SubQStandard (8-week cycle) |
| 2 mg | 40 units | 0.4 mL | Daily SubQAcute focus |
| 5 mg | 100 units | 1 mL | Daily SubQStroke-recovery clinical dose |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
For a 30 mg vial with 3 mL bacteriostatic water, the concentration is 10 mg/mL. A 1 mg dose draws to 10 units (0.1 mL) on a U-100 insulin syringe.
Gently swirl — do not shake. Store at 2–8°C and use within 28 days.
Cycling Protocol
The standard cycle is 1 mg subcutaneous in the morning, 2–3 days per week, for 8 weeks on / 8 weeks off.
Weeks 1–2 (Assessment): Documented protocols begin at 1 mg, 2 days per week, to gauge cognitive response and tolerance. Semax has mild stimulatory effects — community sources describe dosing before cognitive tasks and avoiding late evening dosing.
Weeks 3–8 (Maintenance): Continue at 1 mg, 2–3 days per week based on response. Community sources commonly describe residual cognitive benefits persisting into the off-cycle.
Semax variants: Standard Semax (the original clinically studied heptapeptide), N-Acetyl Semax (NASA, acetylated for improved stability and CNS penetration), and N-Acetyl Semax Amidate (further modified for enhanced potency; less clinical data).
Routes of Administration
Subcutaneous injection is the community alternative, offering more consistent absorption. Standard sites: abdomen, love handles. Use 29–31 gauge insulin syringe.
Stacking Protocols
| Stack | Purpose | Protocol | | --- | --- | --- | | Semax + Selank | Classic Russian stack — focus + calm | Both 1 mg SC, AM, 2–3x/week | | Semax + BPC-157 | Neuroprotective — BDNF + dopamine repair | Semax 1 mg + BPC-157 500 mcg | | Semax + SS-31 | Brain energy — neuroplasticity + mitochondria | Semax 1 mg 2–3x/week + SS-31 500 mcg 5-on/2-off |
Overstimulation is reported when Semax is combined with caffeine or other stimulants. Community sources describe keeping stimulating stacks to the first half of the day.
Side Effects & Safety
- Low toxicity — extensive preclinical and clinical testing in Russia
- No hormonal effects — unlike full ACTH, Semax does not stimulate cortisol or adrenal activity
- No tolerance documented — Russian clinical trial data report consistent efficacy across documented course durations
- Mild nasal irritation — intranasal route
- Slight headache — particularly first 1–2 days
- Mild insomnia — if dosed too late in the day
- Hair loss — community sources describe rare reports at elevated doses, speculatively attributed to melanocortin receptor activity
- Clinical exclusion criteria: Pregnancy/breastfeeding, active malignancy (BDNF/growth-factor interactions noted), acute psychosis (dopaminergic stimulation)
Research Basis
Semax has a substantial clinical evidence base from Russian research institutions.
Dopaminergic and serotonergic activation (Eremin et al., 2005, PMID 16362768): Semax activates brain dopamine and serotonin systems, explaining its nootropic and mood-enhancing effects.
BDNF upregulation (Dolotov et al., 2006, PMID 16996037): A single intranasal dose increases BDNF protein levels 1.4-fold and BDNF mRNA 3-fold in the rat hippocampus, with concurrent trkB receptor activation.
Stroke neuroprotection (Gusev et al., 1999, PMID 10358912): Clinical evaluation as a neuroprotective agent in acute ischemic stroke at 100–150 mcg/kg doses, with angioprotective and neurotrophic activity.
Anti-inflammatory (Dergunova et al., 2021, PMID 34097675): Semax suppresses proinflammatory mediator transcription during brain ischemia.